Back to top
more

Kodiak Sciences (KOD)

(Real Time Quote from BATS)

$3.15 USD

3.15
37,056

+0.13 (4.31%)

Updated Jul 25, 2024 10:50 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kodiak's (KOD) Q1 Earnings Miss, Pipeline in Focus, Stock Up

by Zacks Equity Research

Despite poor first-quarter performance, Kodiak (KOD) stock rises 13% on the strong pace of the tarcocimab clinical programs.

Why Is Kodiak Sciences Inc. (KOD) Down 26.3% Since Last Earnings Report?

by Zacks Equity Research

Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Immunic's (IMUX) Ulcerative Colitis Study Shows Positive Data

by Zacks Equity Research

Immunic (IMUX) reports positive results from the maintenance phase of the phase II study evaluating its lead candidate, vidofludimus calcium, to treat patients with ulcerative colitis.

Palisade (PALI) Enrolls First Patient in LB1148 Study in China

by Zacks Equity Research

Palisade's (PALI) development partner, Newsoara, enrolls first patient in the late-stage clinical study of LB1148 to improve postoperative GI function for patients in China.

InflaRx (IFRX) Stock Up on FDA's EUA for COVID-19 Treatment

by Zacks Equity Research

InflaRx (IFRX) shares gain as it receives emergency-use authorization from the FDA for Gohibic (vilobelimab) to treat COVID-19 in terminally-ill patients.

Kodiak (KOD) Treats First Patient in Diabetic Macular Edema Study

by Zacks Equity Research

Kodiak (KOD) has its first patient in the early-stage study of KSI-501 for treating retinal diseases.

Kodiak Sciences (KOD) Shares are Up 26% in a Week: Here's Why

by Zacks Equity Research

Shares of Kodiak Sciences (KOD) shot up 26% in the last week after the company announced remaining on track with ongoing studies in its fourth-quarter and full-year 2022 earnings report.

Kodiak Sciences Inc. (KOD) Up 1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Does Kodiak Sciences Inc. (KOD) Have the Potential to Rally 87% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at an 87.4% upside potential for Kodiak Sciences Inc. (KOD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 72% Upside in Kodiak Sciences Inc. (KOD): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 72% upside potential for Kodiak Sciences Inc. (KOD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Kodiak Sciences' (KOD) Q3 Earnings Beat, Eye Candidate in Focus

by Zacks Equity Research

Kodiak Sciences (KOD) reports a narrower-than-expected loss for the third quarter of 2022. The focus is on the lead candidate, KSI-301, developed for treating various retinal vascular diseases.

Axsome (AXSM) Q3 Loss Narrower Than Expected, Revenues Miss

by Zacks Equity Research

Axsome (AXSM) reports a narrower-than-expected loss in the third quarter. Revenues comprise sales of the sleep drug, Sunosi, acquired from Jazz.

Amicus (FOLD) Q3 Earnings Beat, Galafold Sales Miss Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) posts a narrower-than-expected loss in the third quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.

Intra-Cellular (ITCI) Beat on Q3 Earnings and Sales Estimates

by Zacks Equity Research

Intra-Cellular Therapeutics (ITCI) posts a narrower-than-expected Q3 loss and sales also beat the mark. ITCI continues to advance its pipeline with developmental programs.

Agios (AGIO) Q3 Loss Narrower Than Expected, Sales Miss

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) posts narrower-than-expected Q3 loss while sales miss estimates. The company is enrolling participants across five pivotal studies evaluating the lead drug Pyrukynd.

Intellia's (NTLA) Q3 Loss Wider Than Expected, Revenues Up Y/Y

by Zacks Equity Research

Intellia Therapeutics (NTLA) posts a wider-than-expected Q3 loss and sales also miss the mark. NTLA continues to advance its pipeline with developmental programs.

Ultragenyx's (RARE) Q3 Earnings Miss Estimates, Revenues Up Y/Y

by Zacks Equity Research

Ultragenyx (RARE) reports a wider-than-expected loss in the third quarter. Revenues, though up year over year, miss estimates.

Repligen (RGEN) Beats Q3 Earnings Estimate, Ups 2022 Guidance

by Zacks Equity Research

Repligen (RGEN) reports encouraging third-quarter results, with sales and earnings beating estimates. RGEN also raises its financial guidance for 2022

Why Is Kodiak Sciences Inc. (KOD) Down 23.8% Since Last Earnings Report?

by Zacks Equity Research

Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Kodiak Sciences (KOD) Rises 60% in Past 3 Months: Here's Why

by Zacks Equity Research

Kodiak Sciences (KOD) has progressed well with the development of its lead pipeline candidate, tarcocimab, for treating various retinal vascular diseases.

Kodiak Sciences (KOD) Focuses on Developing Eye Drug Tarcocimab

by Zacks Equity Research

Kodiak Sciences (KOD) lead pipeline candidate, tarcocimab, being developed for treating various retinal vascular diseases, holds potential. Stiff competition in the market remains a woe.

Kodiak Sciences (KOD) Q2 Earnings Beat, Eye Candidate in Focus

by Zacks Equity Research

Kodiak Sciences (KOD) reports narrower-than-expected loss for the second quarter of 2022. The focus is on the lead candidate, KSI-301, which is being developed for treating various retinal vascular diseases.

Why Is Kodiak Sciences Inc. (KOD) Up 88.3% Since Last Earnings Report?

by Zacks Equity Research

Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Kodiak Sciences (KOD) Q1 Loss Widens, Eye Candidate in Focus

by Zacks Equity Research

Kodiak Sciences (KOD) reports wider-than-expected loss in the first quarter of 2022. Focus is on lead candidate, KSI-301, being developed for treating various retinal vascular diseases.

Should You Buy Kodiak (KOD) Ahead of Earnings?

by Zacks Equity Research

Kodiak (KOD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.